Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice

Infection and Immunity

Volumn 80, Issue 6, 2012, Pages 1958-1968

  Barkan, Daniel ^a   Hedhli, Dorsaf ^b   Yan, Han Guang ^a   Huygen, Kris ^b   Glickman, Michael S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPROPANE; DETERGENT; HYGROMYCIN; KANAMYCIN; METHYLTRANSFERASE; MYCOLIC ACID; MYCOLIC ACID METHYLTRANSFERASE; PHLEOMYCIN; STREPTOMYCIN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CYCLOPROPANE DERIVATIVE; CYTOKINE;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; CONTROLLED STUDY; CYCLOPROPANATION; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; STRESS; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIOLOGY; MUTATION; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BACTERIAL PROTEINS; CYCLOPROPANES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; INFLAMMATION; METHYLTRANSFERASES; MICE; MICE, INBRED C57BL; MUTATION; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84863815961     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00021-12     Document Type: Article

References (33)

1. Alibaud L, et al. 2010. Temperature-dependent regulation of mycolic acid cyclopropanation in saprophytic mycobacteria: role of the Mycobacterium smegmatis 1351 gene (MSMEG_1351) in cis-cyclopropanation of alpha-mycolates. J. Biol. Chem. 285:21698 -21707.
2. Barkan D, Liu Z, Sacchettini JC, Glickman MS. 2009. Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of Mycobacterium tuberculosis. Chem. Biol. 16:499 -509.
3. Barkan D, Rao V, Sukenick GD, Glickman MS. 2010. Redundant function of cmaA2 and mmaA2 in Mycobacterium tuberculosis cis cyclopropanation of oxygenated mycolates. J. Bacteriol. 192:3661-3668.
4. Barry CE, III, et al. 1998. Mycolic acids: structure, biosynthesis and physiological functions. Prog. Lipid Res. 37:143-179.
5. Behr MA, Schroeder BG, Brinkman JN, Slayden RA, Barry CE III. 2000. A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927. J. Bacteriol. 182:3394 -3399.
6. Belley A, et al. 2004. Impact of methoxymycolic acid production by Mycobacterium bovis BCG vaccines. Infect. Immun. 72:2803-2809.
7. Bhatt A, et al. 2007. Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 104:5157-5162.
8. Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P. 1996. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol. 157: 3527-3533.
9. Dao DN, et al. 2008. Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathog. 4:e1000081.
10. Dinadayala P, et al. 2003. Tracking the putative biosynthetic precursors of oxygenated mycolates of Mycobacterium tuberculosis. Structural analysis of fatty acids of a mutant strain devoid of methoxy- and ketomycolates. J. Biol. Chem. 278:7310 -7319.
11. Domenech P, Reed MB. 2009. Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: implications for virulence studies. Microbiology 155:3532-3543.
12. D'Souza S, et al. 2003. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71:483- 493.
13. Dubnau E, et al. 2000. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol. 36:630- 637.
14. Dubnau E, Marrakchi H, Smith I, Daffe M, Quemard A. 1998. Mutations in the cmaB gene are responsible for the absence of methoxymycolic acid in Mycobacterium bovis BCG Pasteur. Mol. Microbiol. 29:1526- 1528.
15. George KM, Yuan Y, Sherman DR, Barry CE III. 1995. The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2. J. Biol. Chem. 270:27292- 27298.
16. Glickman MS. 2003. The mmaA2 gene of Mycobacterium tuberculosis encodes the distal cyclopropane synthase of the alpha-mycolic acid. J. Biol. Chem. 278:7844 -7849.
17. Glickman MS, Cahill SM, Jacobs WR, Jr. 2001. The Mycobacterium tuberculosis cmaA2 gene encodes a mycolic acid trans-cyclopropane synthetase. J. Biol. Chem. 276:2228 -2233.
18. Glickman MS, Cox JS, Jacobs WR, Jr. 2000. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5:717-727.
19. Kirksey MA, et al. 2011. Spontaneous phthiocerol dimycocerosatedeficient variants of Mycobacterium tuberculosis are susceptible to gamma interferon-mediated immunity. Infect. Immun. 79:2829 -2838.
20. Knight ZA, Shokat KM. 2007. Chemical genetics: where genetics and pharmacology meet. Cell 128:425- 430.
21. Korf J, Stoltz A, Verschoor J, De Baetselier P, Grooten J. 2005. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur. J. Immunol. 35: 890-900
22. Korf H, et al. 2009. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J. Clin. Invest. 119: 1626-1637.
23. Pashley CA, Parish T. 2003. Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 229:211-215.
24. Peyron P, et al. 2008. Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog. 4:e1000204.
25. Rao V, Fujiwara N, Porcelli SA, Glickman MS. 2005. Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J. Exp. Med. 201:535- 543.
26. Rao V, Gao F, Chen B, Jacobs WR, Jr, Glickman MS. 2006. Transcyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis-induced inflammation and virulence. J. Clin. Invest. 116:1660 -1667.
27. Romano M, et al. 2006. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 118:321-332.
28. Schnappinger D, et al. 2003. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 198:693-704.
29. Stallings CL, et al. 2009. CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence. Cell 138:146- 159.
30. Vander Beken S, et al. 2011. Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern. Eur. J. Immunol. 41:450-460.
31. Vaubourgeix J, et al. 2009. S-Adenosyl-N-decyl-aminoethyl, a potent bisubstrate inhibitor of Mycobacterium tuberculosis mycolic acid methyltransferases. J. Biol. Chem. 284:19321-19330.
32. Yuan Y, Lee RE, Besra GS, Belisle JT, Barry CE III. 1995. Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 92:6630- 6634.
33. Yuan Y, Zhu Y, Crane DD, Barry CE III. 1998. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol. Microbiol. 29:1449 -1458.